Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 4:05 PM EDTAdvanced RG6501 (OpRegen®) Development in Partnership with Roche and Genentech Published OPC1 Phase 1/2a Clinical Study Results in Journal of Neurosurgery: Spine Completed Key Activities to Support Planned Regulatory Interactions for OPC1 and VAC2 Expanded Collaboration with Advanced BioMatrix for HyStem® Cell Drug Delivery Technology Cash, Cash Equivalents, and Marketable Securities of $72.0 Million as of June 30, 2022 Expected to Provide Capital Through Q2 2024
CARLSBAD, Calif.--(BUSINESS... More



